House Health Hearing
Room 206 at 10:30:00

SB239 repeals Alabama's Medication Assisted Treatment of Opioid Use Act of 2019, removing state rules and a standing working group for buprenorphine treatment of opioid addiction.
It repeals the MAT Act of 2019 (Sections 20-2-300 through 20-2-302), which required the Alabama Board of Medical Examiners to adopt rules governing buprenorphine treatment in nonresidential settings and to use a standing working group to help draft those rules. As a result, state rules governing buprenorphine treatment in nonresidential settings, including aspects like dosage, screening, therapy, and record-keeping, would no longer be in effect. The repeal is intended to address conflicts with changes in federal law and policy governing medication-assisted treatment. The repeal becomes effective on the first day of the third month after passage and governor’s approval.
Enacted
Enrolled
Ready to Enroll
Read a Third Time and Pass
On Third Reading in Second House
Read Second Time in Second House
Reported Out of Committee in Second House
Reported Favorably from House Health
Referred to Committee to House Health
Read First Time in Second House
Read a Third Time and Pass
Read a Third Time and Pass
On Third Reading in House of Origin
Read Second Time in House of Origin
Reported Out of Committee in House of Origin
Reported Favorably from Senate Healthcare
Introduced and Referred to Senate Healthcare
Read First Time in House of Origin
Room 206 at 10:30:00
Room 304 at 12:00:00
Source: Alabama Legislature